Introduction: Reiki is an ancient form of Japanese healing. While this healing method is widely used for a variety of psychologic and physical symptoms, evidence of its effectiveness is scarce and conflicting. The purpose of this systematic review was to try to evaluate whether Reiki produces a significant treatment effect. Methods: Studies were identified using an electronic search of Medline, EMBASE, Cochrane Library, and Google Scholar. Quality of reporting was evaluated using a modified CONSORT Criteria for Herbal Interventions, while methodological quality was assessed using the Jadad Quality score. Data extraction: Two (2) researchers selected articles based on the following features: placebo or other adequate control, clinical investigation on humans, intervention using a Reiki practitioner, and published in English. They independently extracted data on study design, inclusion criteria, type of control, sample size, result, and nature of outcome measures. Results: The modified CONSORT Criteria indicated that all 12 trials meeting the inclusion criteria were lacking in at least one of the three key areas of randomization, blinding, and accountability of all patients, indicating a low quality of reporting. Nine (9) of the 12 trials detected a significant therapeutic effect of the Reiki intervention; however, using the Jadad Quality score, 11 of the 12 studies ranked ''poor.'' Conclusions: The serious methodological and reporting limitations of limited existing Reiki studies preclude a definitive conclusion on its effectiveness. High-quality randomized controlled trials are needed to address the effectiveness of Reiki over placebo.
Introduction

T
here is growing interest in complementary and alternative medicine (CAM). The National Center for Complementary and Alternative Medicine (NCCAM) describes CAM as ''a group of diverse medical and health care systems, practices, and products that are currently not part of conventional medicine.'' 1, 2 Canadians spent an estimated $5.6 billion dollars out of pocket for CAM expenditures in the 12 months ending June 2006 compared to almost $2.8 billion in 1997. 3 Both Gordon 4 and Schiller 5 suggest that the awareness, use, and integration of CAM are beginning to shift from the marginal fringes to the mainstream of care. 6 In a 2007 NCCAM survey, 0.5% of the United States general adult population reported having used Reiki therapy. 1, 7 Reiki is a therapy that claims to provide healing energy to recharge and rebalance the human energy fields, creating optimal conditions needed by the body's natural healing system. 6 Reiki, which is the Japanese term for ''universal life energy,'' is believed to have originated thousands of years ago in Tibet and was re-established in the 1800s after having been forgotten, by Dr. Mikao Usui, a Japanese monk.
Energy-based healing interventions have been found throughout history:
Hippocrates referenced the ''biofield'' of energy flow from people's hands, The Indian Chakra system is based on energy centers in the body, and Eastern energy practices such as qigong rely on the breath to balance the body's energy field to facilitate patient recovery. Reiki practice is administered through a gentle laying on of hands, or in absentia (i.e., remote Reiki where the Reiki practitioner is not present). Both types of practice are based on the assumption that the Reiki practitioner maintains a meditative presence and allows the Reiki energy to flow to where the patient needs it, in a nondirected and nondiagnostic manner. 6 Reiki is typically taught in three levels (sometimes four, as the third level can be broken into part I and part II). 9 The focus of Reiki Level I is on recovering the natural healing abilities of the body. Reiki Level II teaches a deeper understanding of the energetic flow and introduces symbols to aid in treatment efficacy. The third level, Reiki Master, is almost completely focused on the inner spiritual development of the Reiki practitioner and most of the practices at this level concern themselves with the development of spiritual consciousness. Reiki Master training also focuses on the development of the skills needed to teach this work to other Reiki students. A necessary step in all levels is an ''attunement'' by a Reiki Master. The attunement (or initiation) process allows the Reiki energy to flow from the Reiki practitioner's hands to the patient. Without an attunement from a Reiki Master, a person cannot be said to be practicing Reiki, even if they learn the technical aspects of where to put their hands.
Energy-based healing encompasses a belief in a greater healing force and is inherent in many cultures. For example, healing approaches of the indigenous people of China, Tibet, Africa, Native America, and India are thought to work because of the members' belief in the expectation of healing. 10 However, these cultures maintain that healing, like illness, is not limited to those who believe in it, and that an illness is the result of a blockage in one's energy field. By introducing an energy-based intervention, the energy blockage is believed to be removed and this is believed to serve to rebalance the body's energy field, which in turn rebalances the physical body. 10 If there is more to healing than belief, these effects should be able to be measured. Current scientific thinking indicates that the best way to measure the true effect of a biomedical intervention requires proper randomization, control, blinding, and concealment. These processes decrease the likelihood of bias and ensure internal study validity to help determine whether healing claims are more than belief. 10 While Reiki itself is not a biomedical intervention, it is used in the treatment of a variety of psychologic and physical symptoms, which might otherwise be treated with biomedical interventions (e.g., pharmaceutical substances). In this regard, its efficacy needs to be proven.
Reiki proposes to heal the whole patient, and is not directed solely to cure=relieve a single ailment. This whole system healing may require advanced techniques, such as nested qualitative research within a randomized controlled trial (RCT) to measure its effectiveness. 11 Given the complexity of measuring such effects, well-designed, well-executed clinical trials are a prerequisite, and any intentional deviations from the accepted ''gold standard'' RCT should be documented and explained.
Presently, despite increased interest and awareness, the results of specific studies on Reiki are inconclusive. The objectives of this systematic review were to (1) evaluate the quality of reporting of clinical trials using Reiki as the treatment modality and (2) evaluate the quality of existing evidence on the efficacy of Reiki in humans.
Methods
Literature review
Studies were identified by an electronic search of the Medline, EMBASE, and the Cochrane Library databases from their inception to the end of December 2008. The following search terms ( Fig. 1) were employed in MEDLINE Ò :
FIG. 1. Flow diagram of selection process.
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Reiki, Reiki AND randomized controlled trial, Reiki AND clinical trial, Reiki AND clinical, Reiki AND trial. In EMBASE the following terms were used: Reiki.mp, Reiki AND randomized controlled trial, Reiki AND clinical trial. We employed the additional search terms to eliminate all the studies that were not clinical trials. We also used Google and Google Scholar to identify any articles or other publications that may have been missed. The reference lists of the selected articles were checked for additional studies that were not originally found in the search. In addition, given Reiki's Japanese origins, Medline and EMBASE were searched for Reiki studies published in Japanese; however, none were found.
Study selection and data extraction
Two researchers (S.V., V.G.) independently reviewed the list of unique articles for studies that fit the inclusion criteria (see below). The researchers were not blinded to the report name or author. Studies were selected based on the following inclusion criteria:
1. Presence of test group and control group (using either placebo, crossover, sham, or normal care) 2. Human subjects 3. A Reiki healer being responsible for the intervention 4. English language 5. Studies published up to December 2008.
Uncertainties over study inclusion were discussed between the researchers and resolved through consensus.
Quality assessment
Each study was assessed on whether or not it reported a statistically significant outcome measure for the Reiki intervention group. Each study was evaluated and counted only once regardless of how many statistically significant outcome measures it reported. The raw count was used to determine the percentage of studies yielding a statistically significant outcome.
We evaluated the accepted studies using a modified CONSORT (Consolidated Standards of Reporting Trials) Criteria for Herbal Interventions. 12 The original CONSORT was developed by a group of scientists and editors to improve the quality of reporting of RCTs. 13 The CONSORT for Herbal Interventions was developed to aid editors and reviewers in assessing the internal=external validity and reproducibility of herbal medicine trials, allowing an accurate assessment of safety and efficacy. 12 The authors chose the CONSORT for Herbal Interventions (HI) because it specifically breaks out important details about the Intervention, which adds important information about the Reiki trials. For example, the CONSORT for HI specifically details (1) dosage and frequency: Interpreted as how long the Reiki session lasted, and how many Reiki sessions were given; (2) practitioner: What is the level of training of the Reiki practitioner as well as the number of years of experience; (3) placebo or control: Reiki is usually administered by having a person present in a room with a patient (except not in the case of distant Reiki). Reiki placebo is important in determining whether the patients and assessors were blinded.
One researcher (S.V.) modified the herbal dosage components of the CONSORT for HI, to reflect the Reiki practitioner as the intervention instead of the herb (see Table 1 Original CONSORT for HI and Table 2 for modified CONSORT for HI).
For each CONSORT criterion, the 2 researchers independently assessed whether the reporting was adequate or not and scored the criterion as: Y (yes), N (no), P (partial), or NA (not applicable). We identified items that were adequately or not adequately reported according to the CONSORT definition of what is required for each item.
We considered the percentage of affirmative answers as the raw score for the internal validity. A percentage calculation was used to determine the proportion of CONSORT criteria that are adequately addressed. Items that were rated as NA were excluded from the analysis.
To assess the methodological quality of existing Reiki studies, we used the Jadad score. The Jadad score is the method most authors use to assess methodological quality. 14 This validated score ranges between 0 and 5. Studies are scored according to the presence of the three key methodological features of randomization, blinding, and accountability of all patients, including withdrawals (essentially subsets of the greater CONSORT criteria). Criteria are given a ''0'' or ''1'' score based on the absence or presence of the criteria. Scores are interpreted as: 0-2: poor methodological quality; 3-4 good methodological quality; and 5 excellent methodological quality. 15 
Results
A total of 485 unique articles were identified using Reiki as the only search term. To limit the articles to clinical trials only, we employed additional search terms as described above. As a result, study count was reduced to 76 (Fig. 1 ). The majority of these studies were either (a) small studies with no control arm, (b) descriptive case studies where researchers described a single patient Reiki intervention and=or recounted its history, or (c) studies using Therapeutic Touch (a similar but distinct therapy) and thus were excluded. Thirteen (13) studies fulfilled the aforementioned inclusion criteria. One study 16 was removed from the analysis because the intervention included two different types of practitioners (Reiki and Le Shan) and thus the results of the Reiki practitioner could not be isolated. This left a total of 12 studies to analyze.
Since four of the studies did not indicate the level of experience and=or the number of years of experience of the Reiki practitioner, the researchers attempted to contact the primary authors to obtain this information. The researchers were successful in contacting two of the authors, 17, 18 and unsuccessful with authors for two of the studies. 19, 20 All of the studies differed in their studied populations and outcome measures. Of the 12 studies, 3 studies administered Reiki for physiological symptoms such as stroke recovery, seizure rate and heart rate and 9 studies administered Reiki for psychological symptoms such as anxiety and depression. A total of 31 different outcome measures were evaluated in the trials, none of which were used in more than 3 studies (Table 3) . Hence, the heterogeneity of the studies' outcomes precluded a formal meta-analysis.
CONSORT reporting quality: Findings
The evaluators disagreed in 33% of the evaluations, with the majority of the disagreements resulting from a difference in interpretation in what constituted partial (p) versus full (y) rating for the CONSORT analysis. After consensus discussions, the remaining disagreements (1%) were resolved by a third researcher (S.N.W.). The 12 trials that studied a Reiki intervention in either a randomized controlled fashion or as a test versus control experiment are presented in Table 3 . Eight (8) of the 12 studies identified themselves as RCTs. However, upon analysis of each of the study's text, the researchers were only able to identify 5 of the 12 (42%) publications as true RCTs. [20] [21] [22] [23] [24] Individual total applicable CONSORT criteria varied by study (see Table 2 for an individualized reporting of each criterion and Table 3 for a summary of adequately reported criteria by study).
Fifteen percent (15%) of the CONSORT Criteria items were not applicable for many of the trials (e.g., interim analyses, Intervention-Dosage regimen 5 y y y y y p y y y y p y 10 0 2 0 4e
Intervention-Control group 6 y y y y y y y y p y y y 11 0 1 0 4f
Intervention-Practitioner 7 n y y p y n p y y y n y 7 3 2 0 5
Primary and secondary objectives defined 8 y y y y y y y y y y y y 12 0 0 0 6 Outcomes 9 p y p y n y y y y p y y 8 1 3 0 6b
Quality enhancement of the outcome measurement 10 y y y y y y y y y y y y 12 0 0 0 7 Sample size determination 11 n y n y n n y y n n n n 4 8 0 0 7b
Interim analysis and stopping rules (if applicable) 12 na na na na na na na na na na na na 0 0 0 12 8 Randomization sequence allocation 13 n n n y y n y n n n n y 4 8 0 0 8b
Details of restriction (if applicable) 14 na na na na na na y na na y na y 3 0 0 9 9
Allocation concealment 15 n n p p n n y n n n n y 2 8 2 0 10
Who generated the allocation sequence? 16 n n n n y n y n n n n y 3 9 0 0 10b
Who enrolled the patients? 17 n n n y y n y n n n n y 4 8 0 0 10c
Who assigned the patents to the groups? 18 n n n n y n n n n n n n 1 11 0 0 11 Blinding (were participants blinded?) 19 y y y n n n n n n y y y 6 6 0 0 11b
Blinding (were the assessors blinded?) 20 n n y p n n y n n n n y 3
Was success of blinding evaluated? 21 n y n na na na na na na n n n Was it intention-to-treat analysis? 28 n y n n n n y y y y n n 5 Table 2 ). The remaining items were either not reported at all (32%) or reported partially (16%). As a group, the 12 studies reported adequately the Introduction, the beginning part of the Methods section (CONSORT items [3] [4] [5] [6] [7] [8] [9] [10] , and most of the Results. Other than this, all the other sections were reported less than adequately: Methods-randomization, concealment and blinding (CONSORT items 11-22: 39% of items reported adequately); Results (specifically Intention-to-Treat: 42% adequately reported and Recruitment Dates: 25% adequately reported); and the Discussion section (56% of items reported adequately). Individual studies ranged from 31% to 84% in adequately reporting applicable criteria. Assessment scores for all CONSORT criteria in the 12 trials are shown in Table 3 .
Items reported adequately
The 12 trials adequately reported issues that are defined in the Introduction and beginning of Methods (all Methods except for Randomization, Assignment, and Blinding). These include: Reiki historical context with supporting literature, problem definition, study objectives, participant eligibility, description of participants and control subjects, dosage regimen for intervention and differences from control group treatment, and quality enhancements undertaken to improve outcome measurement. Over half the studies gave details about the practitioner performing the intervention.
Select criteria from the Results and Comments section were also adequately reported. These included: demographic and clinical characteristics of the groups, discussion, and generalization of the results. The number of patients in each group was almost always explicitly stated. The majority of studies reported mean scores and p-values, but less than half reported confidence intervals. The CONSORT criteria explicitly state that reporting p-values alone is not sufficient. Researchers must report confidence intervals so that readers can easily discern the overlap between mean scores.
Items seldom reported adequately
We identified major shortcomings in the reporting of the items displayed in the latter part of the Methods section (i.e., reporting the Randomization, Assignment, and Blinding). Only four trials [20] [21] [22] , * adequately detailed the randomization process. Of those four trials, only two trials 20, * described the concealment of the allocation. For allocation concealment, we assumed that when no data were present, allocation was not concealed. A distinction was made between the two trials 20, * where allocation was clearly concealed and those where there is some mention of concealment, but it is unclear whether this was achieved adequately.
Other examples of inadequate reporting: three trials 20,22, * detailed who generated the allocation sequence and only one trial 22 specified who assigned the patients to their groups. Six trials 17, 18, 23, 24, 25 , * implemented blinding procedures for participants, but only one of them measured the success of the blinding. 25 Three (3) trials 20, 21, 23 mention blinding assessors. One trial (25) provided extensive background on the process and success of therapist blinding (for Reiki Level I practitioners) but only stated ''patients were blinded'' for the participant description. The CONSORT clearly states that this sentence is not enough to ensure that adequate blinding was achieved. The researchers rated this criterion for this trial as partially (p) adequately reported. In the other trials, masking of the participants or the therapists was not achieved due to a lack of a placebo arm (only a test and a control group).
Eight (8) trials identified specific primary outcome measures, but of these trials only four studies 20, 21, 25, 26 provided a full rationale for sample-size calculation. On the basis of the reported numbers in the whole participant flow, we inferred that an intention-to-treat analysis was present in 5 of the trials. 20, 24, [25] [26] [27] Three (3) trials 21,24, * mentioned the date range of the patient recruitment.
Jadad methodological quality: Findings
Based on the Jadad scores, 11 of the 12 studies were rated as methodologically ''poor'' with one study (20) rated as good. No studies were rated as ''excellent'' (Table 4 ).
Study results linked to level and experience of Reiki practitioner
Of the 128 studies evaluated, 9 stated significant positive findings on at least one outcome measure (not necessarily the primary outcome, as this often was not stated), while the other 3 studies 18, 20, 25 showed no significant outcomes (Table 5) .
Of the three studies that showed no significant effect of Reiki, one 25 utilized a Reiki Master and 14 Level I Reiki practitioners; one used multiple Reiki Masters 18 and the other study 20 utilized 6 Level I or II Reiki practitioners. Of the 9 studies that showed a significant positive Reiki effect, 8 used a Reiki Master (or a Level II Reiki practitioner with more than 3 years experience). For the remaining study, 19 the researchers were not successful in their attempts to contact the author to determine the information (i.e., level of training or years of experience of the Reiki practitioner). As far as we could tell, no significant positive findings were found with Level I or II Reiki practitioners with less than 3 years of experience.
Discussion
Reiki use by patients in North America is growing; however, as shown by our analysis, this trend is not supported by adequate scientific data. There are few studies available to evaluate the efficacy of Reiki. Moreover, the few studies that are available are almost invariably of poor quality. Our analysis shows that the most important aspects that determine study quality (randomization, blinding, and accountability of all patients) are not well reported, nor is Neither test nor control group showed pretest signs of depression or anxiety.
(continued) Tentative positive results supports a larger study.
their absence discussed in any of the Reiki studies, a fact that greatly diminishes the quality assessment of these trials. We were only able to uncover 12 studies on which to perform our evaluation; these 12 studies had 31 different outcomes. This clearly shows that Reiki researchers are in ''exploratory mode'' in terms of understanding the benefits of Reiki. Although most of the outcomes indicated a positive outcome, it is quite possible that bias against the null hypothesis and the ''file drawer syndrome'' resulted in an unknown number of negative trials on Reiki never being published. 28 Hence, to further evaluate the validity of claimed therapeutic effects of Reiki, trials are needed with larger study populations and better reporting quality. It is obvious that these trials should be registered with a clinical trials register to avoid publication bias. In contrast, some researchers might argue that such studies should not be performed at all, since the biological substrate for Reiki's effect is unknown and plausible at best. However, while it may be difficult to scientifically assess Reiki's method of action with our current technology, it is possible to determine Reiki's efficacy. Given the increase in patient spending in CAM, we believe it is our job as researchers to conduct good quality trials which add to or refute the efficacy data of a given therapy.
Western medicine operates under the paradigm of evidencebased medicine. RCTs are considered the ''gold standard'' for providing evidence on effectiveness of biomedical interventions. 29 While Reiki itself is not a biomedical intervention, its efficacy needs to be proven, in service of good science. Current literature has suggested that RCTs alone may be limited in their ability to measure ''whole person'' healing, which is characteristic of CAM therapies (such as Reiki). 11 Adequate standards of reporting are necessary so that readers can make assessments on the internal and external validity of the trial as well as properly assess the results. The CONSORT statement was developed to aid authors in adequately reporting (and hopefully designing) their studies. In general, current reporting of trials is not considered adequate. In a study that looked at 253 RCTs reported in 5 leading medical journals (which have actively embraced the CONSORT) between 2002 and 2003, less than 60% of the trials adequately reported on allocation concealment (48%), randomization implementation (55%), blinding status of participants (40%), blinding of health care providers (17%), and blinding of outcome assessors (47%). 30 Our findings are in agreement with an earlier observation that reporting of CAM trials is also poor. 31 In a project that assessed a sample of 206 RCTs of herbal medicine interventions, less than one third adequately reported whether those administering the intervention were blinded (28%), the methods for implementation (22%), and generation of the random allocation sequence (21%), whether there were protocol deviations (18%) or whether outcome assessors were blinded (14%). 29 Biofield Energy Therapies are controversial to conventional health care providers and policymakers for two main reasons: (1) the dearth of rigorous scientific data that support or refute their efficacy, and (2) because biofields currently cannot be measured, so their scientific method of action remains questionable. While the second point may take more time to resolve, the first point can be addressed immediately, through adequate scientific reporting. In order for efficacy to be scientifically recognized, adequate reporting is required to inform readers of the purposeful deviations from traditional RCT design so readers can judge the influence of methodological flaws on the results of trials. In order to be accepted as true scientific evidence, adequate reporting of future Reiki RCTs or mixed methods RCTs is crucial. Of the items that were not reported adequately, all of them were reported adequately in at least one study, indicating that it is possible to report adequately.
A potentially significant finding from this study is that the level of training and=or years of experience of the Reiki practitioner seemed to be important for Reiki to be effective. A finding from the Efficacy of Distant Healing suggests that healers should have at least 3 years of practice to be considered performing optimally. 32 While the author of this study was not specifically referring to Reiki practitioners, it does make sense that a certain level of expertise improves the Reiki practitioners' efficacy.
We exempted Reiki Masters from the ''3 years of practice'' criteria that we applied to Reiki Practitioners (Level I and Level II) due to the intensive training that it takes to become a Reiki Master. Level II training is usually only given after a student has been practicing Level I Reiki for at least 3 months, though this can vary somewhat depending on the individual. Reiki Master training is primarily intended for people who have made Reiki their life's work. Depending upon the individual, Reiki Master level training is usually given only after a student has been practicing Level II Reiki for at least 1 year and the training is quite intensive. 9 Studies that used Reiki practitioners (Level I or II) with less than 3 years experience showed no significant outcome, while in all but one of the studies that used a Reiki Master, there was a significant difference in measured outcome in the Reiki group. The goal of Reiki is to direct healing energy into the recipient. It has been suggested that the number of changes of Extra-Low Frequency (ELF) Magnetic Fields coming from Reiki practitioners' (i.e. Level I or Level II; nonReiki Masters) hands differs significantly than the number of changes of ELFs coming from Reiki Masters' hands; however, the results of these studies have only been published in abstract and book form. 33 Although this is not a definitive test for efficacy of Reiki healers (no known test exists as far as we know), this does suggest that there is a difference between Reiki Masters and non-Master Reiki practitioners.
Conclusions
In order for Reiki studies to be evaluated and accepted based on their stated outcomes, authors need to ensure that the methodological quality and reporting of the study are adequate. This will only be achieved when authors are educated and disciplined in their approach to designing, executing, and reporting their studies. Alternative therapy journals should also actively embrace the CONSORT criteria to ensure that CAM therapies are reported at the highest scientifically accepted level. To date, based on the poor quality of studies and their reporting, it is currently impossible to draw definitive conclusions about the efficacy of Reiki.
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VANDERVAART ET AL. North America are delivered via Caesarean section (C-section). Though a common surgical procedure, C-section recovery can be painful. Opioids, specifically codeine, are commonly used to ease pain; however, its active metabolite, morphine, passes into breast milk, and may produce unwanted side effects in neonates; therefore, alternatives to opioids are being sought.
Reiki is an ancient Japanese form of healing where practitioners transfer healing energy through light touch and positive healing intention. Although 1.2 million Americans use reiki to reduce pain or depression, there is a lack of strong evidence supporting its effectiveness. A recent systematic review showed existing studies to be of poor methodological quality, with the common limitation of lack of blinding. To overcome this issue, the authors used distant reiki to assess its effectiveness in reducing pain following an elective C-section.
Methods: In this randomised, double-blinded study, women who underwent an elective C-section were allocated to either usual care (control, n¼40) or three distant reiki sessions in addition to usual care (n¼40). Pain was assessed using a visual analogue scale (VAS). Conclusion: Distant reiki had no significant effect on pain following an elective C-section.
Clinical Trial Registration Number: ISRCTN79265996.
< Prepublication history for this paper is available online.
To view these files please visit the journal online (http:// bmjopen.bmj.com).
ARTICLE SUMMARY Article focus
-This is the first randomised, double-blinded trial conducted on distant reiki. -The focus in on distant reiki's effects on pain after Caesarean section. -Special attention was paid to the methods of proper randomisation, patient allocation concealment and blinding.
Key messages -Our trial suggests that distant reiki had no benefit in reducing patients' postpartum pain over usual care for elective Caesarean section.
Strengths and limitations of this study
-We engaged a highly experienced reiki master to administer distant reiki removing the placebo effect which was present in all other pain trials. In addition, we maintained a high adherence to protocol, successful blinding of the research team, successful randomisation and patient allocation concealment, and diligent data collection with extremely few data points missed. We had good credibility with research participants, as all but 10 women refused to participate. We evaluated other aspects of healing after elective Caesarean section, beyond patients' perceived pain levels, by including the previously developed and published Milestone Questionnaire. -A potential limitation was the magnitude of pain on which we were attempting to show an impact. Just as acetaminophen is not suitable as pain medication after Caesarean section, distant reiki may also not be suitable for this magnitude of pain. In addition, since some patients were discharged early, our complete dataset is limited to 48 h, with gaps in data for 16 patients (20%) accounted for by carrying the last pain score forward. To ensure that this method did not distort the results, we also evaluated AUC for pain on day 1 and day 2 individually and found no differences between groups for both these time periods. INTRODUCTION Approximately 25% of all babies in North America are delivered via Caesarean section (C-section) 1 ; alleviating pain early is important, as studies have shown that postoperative pain negatively affects a mother's ability to care for and breastfeed her infant. 2 To alleviate postoperative pain, opioids are commonly used after Csection. 3 For example, codeine, a common opioid, is a prodrug, and it is the relative biotransformation of codeine into morphine by the highly polymorphic cytochrome P450 enzyme 2D6 (CYP2D6) that is the single most important factor determining codeine analgesia in adults. Approximately 5e10% of ingested codeine is converted into morphine; however, this percentage can increase dramatically in individuals who have multiple copies of the CYP2D6 allele. 4 We now know that morphine passes into breast milk. In 2005, a published study alerted the medical community to a case where a full-term breast-fed baby died from a morphine overdose as a result of his mother taking Tylenol no 3 with codeine to manage her pain; the mother had several copies of the CYP2D6 allele and had converted more than 10% of codeine into morphine. 5 6 Maternal breast milk is considered the optimal nutrition for infants, and the American Academy of Pediatrics recommends exclusive breastfeeding for the first 6 months of life. 7 To ensure that all mothers who are recovering from C-sections and wish to breastfeed are able to do so safely, alternatives to opioids are sought.
Several complementary and alternative medicine therapies are used to alleviate pain. In an attempt to reduce or eliminate the need for opioid pain medication, we sought to examine the effect of distant reiki on pain. Reiki, an ancient Japanese form of hands-on healing, used to alleviate pain and depression, 8 is classified as an Energy Medicine by the National Center for Complementary and Alternative Medicine (NCCAM). 9 Despite being an ancient Japanese practice, reiki is practised by over 1.5 million Americans, and its popularity is growing. 10 It was promoted by Dr Oz, prominent cardiothoracic surgeon, host of the Dr Oz Show and frequent Oprah guest, as his 'ultimate complementary and alternative medicine therapy for 2010.' 11 However, while it is commonly practised, there is no agreed-upon theory for how reiki might work, and its mechanism of action is still unknown. 8 Reiki practitioners believe that they can direct healing energy through their hands to their patients. To direct this energy, practitioners maintain a meditative presence and place their hands lightly over the person they are treating to aid in the patient's natural ability to heal. Reiki can be practised either proximally, with the patient located beside the practitioner, or distally, with the patient and practitioner in separate locations. Both types of reiki rely on the premise of a universal source of healing energy which a reiki practitioner can direct through intention.
A distant reiki treatment is like distant prayer, in that the practitioners are thinking of their patients from a distance. In distant reiki, reiki practitioners first undertake a specific protocol which allows them to send the healing energy to the patient. Second, practitioners mentally ask the person who is absent if he or she consents to treatment. Lastly, if practitioners do not hear a response or if they hear 'yes' in their head, they follow the same procedure as for traditional reiki, but they place their hands on a substitute (eg, pillow) for the person being treated; if they hear 'no,' the session ends immediately.
Reiki may work. Several studies have found a reduction in pain when using reiki 12e15 ; furthermore, one of the studies found that women who received reiki after hysterectomy reported less pain and requested fewer analgesics. 12 While there were no studies which specifically evaluated distant reiki for pain, one study found that distant reiki was as effective as traditional reiki in the management of depression and anxiety. The authors concluded that the distant reiki was as efficacious as traditional reiki, and the healing power of reiki was not due to placebo. 16 However, despite widespread and growing popularity, there is a dearth of well-conducted published scientific literature supporting or refuting reiki's efficacy. A recent systematic review of reiki found that while the vast majority of studies had positive therapeutic effects, all available studies scored poorly when methodological quality was measured using Jadad 8 ; thus, definitive conclusions about efficacy could not be made. A common source of potential bias was the lack of blinding of participants and assessors when using traditional reiki. Patient and medical-staff blinding to treatment allocation in a clinical trial is particularly important when the response criteria are subjective, such as alleviation of pain. 17 To overcome this limitation, we employed distant reiki in our trial.
Given the need for alternate pain-control treatments for breastfeeding mothers owing to the risk of morphine exposure in neonates, and the reduced pain observed in the women who received reiki after hysterectomy, our objective was to determine if distant reiki is effective in reducing pain after elective C-section, through a randomised double-blinded study.
METHODOLOGY Study design
This was a double-blinded randomised clinical trial. The investigators, participants and healthcare staff directly involved with the participants were unaware of the group assignments. The study was approved by the research ethics board at St Michael's Hospital in Toronto, and all participants provided written informed consent prior to participation.
Participants
All pregnant women who were scheduled to have an elective C-section were approached during a routine prenatal visit at the obstetrical clinic at St Michael's Hospital between 1 September 2008 and 31 March 2009. Criteria for exclusion included the following: having had previous experience with reiki or not planning to use standard postoperative pain medication. Women were recruited in either English or Spanish, and those who did speak other languages were approached if they had a translator with them, such as a husband or friend.
To ensure concealment of group assignment, the St Michael's Hospital research associate (SvdV) enrolled participants and then contacted the research assistant (YIG) at The Hospital for Sick Children with the participant's information (unique Hospital ID, date and time of C-section) for randomisation. YIG had previously generated the randomised number sequence in blocks of four or six. Participants were sequentially assigned (by YIG) to the random sequence, which was securely stored and password-protected on the Hospital for Sick Children network. If the patient was assigned to the distant reiki group, the research assistant (YIG) contacted the reiki master with the participant's information. If the patient was in the control group, no contact was made with the reiki master.
Intervention
Participants in the control group received usual medical and nursing care during their stay (typically 72 h). The intervention group received usual care plus three distant reiki sessions, one each morning. The first session was administered on the morning of the C-section, at least 30 min prior to surgery, and the second and third sessions were administered on the following mornings at approximately 08:00.
A single reiki master located over 100 km away, who was trained in the Usui line of reiki and has been practising reiki for over 10 years and regularly treats clients with distant reiki, administered the distant reiki interventions. Each distant reiki session lasted approximately 20 min, and the reiki master followed the traditional Usui reiki protocol for distant healing. 18 The unique Hospital ID was used as the identifier when sending distant reiki to the participant.
C-section, anaesthesia and analgesia protocol
All elective C-sections at St Michael's Hospital were performed using the Pfannenstiel protocol. 19 Women who underwent elective C-sections received spinal anaesthesia with 0.75% bupivicaine, and 15 mg of fentanyl lasting 2e4 h followed by 100 mg of epidurally administered morphine, which typically lasts 12 h. Vital signs were checked, and pain and sedation scores were taken every 10 min for 2 h after the C-section. Following these 2 h, vital signs were taken every 12 h on the delivery ward.
The following analgesia protocol was administered immediately following the C-section: 1. Naproxen (500 mg) was given rectally and then orally every 12 h for 48 h. 
Outcome measures
A research associate collected baseline ethnodemographic and pain-history data, while a nurse measured baseline vital signs prior to surgery and prior to first distant reiki treatment. All personal patient information was deidentified by a numeric code to protect patient confidentiality.
The primary endpoint for the study was the area under the curve (AUC) for pain (in movement) for days 1e3 using the visual analogue scale (VAS), 20 21 corresponding to a person's total pain. The VAS is a 10 cm line with an anchor at each end. Under the anchor on the left-hand side is '0: no pain,' and under the anchor on the right-hand side is '10: worst pain.' A research assistant collected two sets of pain scores three times each day (07:30e09:30; 12:00e14:30; and 17:30e20:00). The two sets of pain scores corresponded to the amount of pain felt at that moment in rest, and the amount of pain felt when moving. In addition, each morning, participants were asked to indicate the worst level of pain felt during the night.
Secondary endpoints included the following 10 measures: AUC for pain in motion for days 1, 2 and 3 separately; the mean VAS (in motion) from days 1e3; the mean VAS (in rest) from days 1e3; the number of patients in need of opioid pain medication; the dose of codeine equivalent consumed per kilogram of body weight; the number of adverse events to opioids such as constipation or itchiness; mother's respiratory rate, heart rate and blood pressure (systolic and diastolic); and the time to first activity (first hunger, first spontaneous voiding, first eating solid foods, first walk, etc) using the Milestone Questionnaire. The Milestone Questionnaire was previously used on women post elective C-section to evaluate their rate of healing. 22 As reiki is used not only for pain, but also to send 'healing energy to where the body needs it most,' 23 this activity milestone questionnaire was used to capture additional healing that could have taken place.
Statistical analysis
Reporting adhered to the Consolidated Standards of Reporting Trials statement for reports of parallel-group randomised designs. 24 The Area Under the VAS-Time Curve was calculated by plotting the VAS scores on the timescale and dividing the curve into a series of trapezoids (figure 1). Opioid medications were converted to codeine equivalents (60 mg of oral codeine was considered equivalent to 10 mg of oral morphine and 6.7 mg of oxycodone). 25 26 All analyses were performed by intention to treat. We calculated that 40 participants per group would be required for the study to have 80% power to show a clinically significant 25% mean reduction in pain with distant reiki as compared with placebo. A 25% mean pain reduction was determined a priori to be clinically relevant by our expert clinicians, since the literature concludes that 20e33% reduction is considered clinically significant. 27e29 For power analysis, we used an SD in pain of 56% in the normal postoperative C-section population. 30 Baseline demographic and outcome variables were compared using the Student t test, ManneWhitney U test or Fisher exact test where appropriate. For missing data, we used the last-observation-carried-forward method in the analysis of AUC and mean pain scores.
RESULTS
One hundred and thirty women were eligible for participation in this study, 47 women were excluded (did not meet inclusion criteria, refused or did not speak English/Spanish), and 83 women were enrolled (figure 2). A total of 42 women were randomised to receive distant reiki, and 41 women were randomised into the control group. Three women were withdrawn from the study after randomisation: one woman (control group) was withdrawn, as she suffered a severe haemorrhage during surgery and remained in the ICU for several days, leaving researchers unable to collect her pain-score data; two participants were withdrawn from the distant reiki group, as they received general anaesthesia instead of spinal anaesthesia (thus, they no longer met inclusion criteria). This left a total of 40 women randomised into each group. No patients mentally refused the distant reiki intervention, and the two groups did not differ significantly in baseline measures or demographic characteristics (table 1) except for birth weight of newborns (p<0.001); differences between groups in maternal age approached significance (p¼0.06).
During days 1 and 2, a total of three pain scores, which represented less than 1% of the data, were not collected because the patients were sleeping during the time to record their level of pain; all other data for patients were captured (pain medication consumption, physiological measures and time to first activity) on these days. However, on day 3, a total of 16 patients (20%), eight from the distant reiki group and eight from the control group, were discharged early (after 48 h instead of after 72 h in hospital) resulting in 20% missing data (pain scores, pain medication consumption and time to first activity). AUC pain data were not compared between distant reiki and control groups for day 3 alone, owing to the large amount of missing data.
No significant difference was seen between groups in the primary outcome of overall pain from days 1e3. The mean (6SD) AUCs for pain for days 1e3 in the distant reiki and control group were 2126104 and 2236118 respectively (p¼0.96). There were no significant differences between groups in AUC for pain for day 1 or day 2, mean VAS pain scores (in rest or in motion), use of opioids, dose (mg/kg body weight) of opioid medication consumed or time to first activity (table 2) . The main outcome and most secondary outcomes were normally distributed, with the notable exception of pain-medication consumption and adverse events which were not normally distributed.
To determine if the two variables which varied between the two groups (baby birth weight and mother's age) affected the primary outcome, we performed a multivariate regression analysis with three independent variables; mother's age, baby's birth weight and group allocation were regressed against the dependent variable: AUC of pain for days 1e3. Both baby's birth weight and mother's age were found to be significant (p¼0.013, p¼0.046 respectively), while the distant reiki group allocation was still not significant (p¼0.558).
There was a small but significant difference in heart rate on day 1, 4 h after C-section (see figure 3 for timeline), whereby the mean (6SD) heart rate in the distant reiki group was 74.368.1 bpm compared with 79.867.9 bpm in the control group (p¼0.003). Systolic blood pressure on day 3 at 08:00 was also significantly lower in the distant reiki group (106.469.7 mm Hg) compared with the control group (111.9611.0 mm Hg) (p¼0.02). Otherwise, there were no significant differences between groups in the physiological measures.
There were no significant differences in the rates of adverse events between the two groups.
DISCUSSION
This study measured perceived pain and healing in women over their 3 days in hospital, while they recovered from an elective C-section. We found no beneficial effect of distant reiki over usual care for pain reduction up to 3 days after elective C-section.
The lack of an observed benefit of distant reiki for all pain outcome measures at all points in time is in contrast to most, 12e15 but not all, 31 earlier reiki pain studies. However, unlike all earlier published studies, our study differed in two key regards: firstly, ours was the only randomised and double-blinded trial. In addition to the patients not knowing their group assignment, the investigators and outcome assessors were unaware of the intervention assignment. This suggests that the therapeutic benefit of reiki for pain observed in previous, non-blinded studies was a placebo effect or that the magnitude of pain from an elective C-section is too great for distant reiki to make an impact.
Secondly, we employed distant reiki, and not traditional hands-on reiki, as our intervention. In considering the physiological effects of reiki, one of the basic teachings of healing with reiki is that we are more than our physical bodies. We also have an energy body made up of our aura (energy fields), the chakras (energy centres) and the meridians (energy pathways). Because reiki healers believe that reiki energy is not limited by time and distance, distant reiki healings can also be given without the client being present. 18 Reiki practitioners assert that a distant reiki intervention works by directing healing energy which engages the body by generating biological reactions such as pain reduction.
It is well accepted that many constituents of living systems communicate with each other via electromagnetic signals. A number of studies have demonstrated that weak electromagnetic fields (EMF) are capable of eliciting in vivo and in vitro effects from different biological systems. Endogenous electromagnetic and magnetic fields are associated with many basic physiological processes, ranging from ion binding and molecular conformation in the cell membrane to the macroscopic mechanical properties of tissues. In an attempt to validate energy therapies such as reiki, researchers have been measuring classical electromagnetic (EM) fields emitted by the body using both physical 42e45 and biological 46 detectors. However, the intensity of these fields fades rapidly with distance, and thus cannot explain the effect of distant reiki.
One author 47 has proposed that in addition to classical EM fields, the body generates non-classical and quantum fields, which do not fade with distance. Several studies have shown that quantum fields can influence neurological 48 and immunological functions 49 at the cellular level. However, the idea that reiki energy works through quantum fields is highly controversial, and more scientific trials need to be conducted in this area.
Another possible explanation for the lack of observed effect is the study's sample size. Based on our calculations, the distant reiki would have had needed to have an effect size of 0.55; however, based on the AUC for pain, distant reiki had an effect size of 0.1, which is considered to be very small. Using this effect size, a total of 2530 patients (1265 per group) would have been needed to see a significant difference between groups. It is unlikely that the failure to find significant differences is due to selection bias, as only 10 women (12.5%) refused to participate in the study.
The Milestone Questionnaire which recorded time to first activity also showed no differences between groups. We evaluated these responses against the measures obtained by Roseag and colleagues, 22 and found all rates of healing to be similar to their published results, except for time to first eating solid foods, where our study showed an average of 10 h longer for both groups. This could be due to the fact that St Michael's Hospital does not routinely allow women to eat solid foods until after they have passed gas, regardless of whether or not they are hungry.
Despite randomisation, there was a statistically significant difference between the two groups in birth weight; differences in maternal age approached significance. Our finding that a mother's perceived pain decreases with maternal age is consistent with previous studies. 50 51 However, we could not find any literature to support or refute the finding that larger babies born via elective C-section caused more pain. The increase in mothers' pain could be due to larger uteri which housed larger babies, thereby resulting in more pain as they contracted back to normal. In addition, lifting heavier babies post surgery could result in more pain for a recovering mother.
Heart rate taken approximately 4 h after C-section and systolic blood pressure taken on day 3 at 08:00 (table 2) were significantly lower in the distant reiki group compared with the control group. This is consistent with three studies, 13 two of which 52 53 specifically examined the physiological changes as a result of reiki. However, given that distant reiki's method of action is unknown, there is the possibility that our findings are simply due to chance, given the number of secondary measures evaluated. The small but statistically significant benefits of lower heart rate and blood-pressure levels are unlikely to be clinically significant but may be interesting to future researchers who are searching for a mechanism of action for distant reiki.
The generalisability of our study may be limited, given that one reiki master performed all of the distant reiki treatments; in addition, given the absence of information about the mechanism of action of distant reiki, we chose the same dosage that in a published trial using traditional reiki. 12 Outcomes may differ given other reiki practitioners and other dosage regimes.
CONCLUSION
In conclusion, our trial showed no significant benefit of distant reiki (administered once per day) over usual care for pain management in the first 3 days after elective Csection. It is not recommended as a method of primary pain relief for women undergoing an elective C-section.
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genotype and codeine analgesia among women recovering from c-section.
Methods: Forty-five mothers prescribed codeine provided a blood sample for CYP2D6 genotyping and recorded their pain level 4 times a day for 3 days immediately after a c-section. Codeine was used on an as-needed basis; doses and times were recorded. The relationship between CYP2D6 genotype, pain scores, need for codeine, and adverse events was studied. Theoretical morphine dose, based on CYP2D6 genotype, was estimated.
Results: Women at the genotypic extremes reported codeine effects consistent with their genotype: the 2 PMs of codeine reported no analgesia as a result of taking codeine, whereas 2 of the 3 UMs reported immediate pain relief from codeine but stopped taking it due to dizziness and constipation. Much larger numbers are needed to study similar correlations among extensive and intermediate metabolizers.
Conclusions:
In this pilot study, the extreme CYP2D6 genotypes (PMs and UMs) seemed to predict pain response and adverse events. Larger sample sizes are needed to correlate the range of genotypes with pain response.
INTRODUCTION
Pain is a major public health issue, and it is the most common reason for physician consultation in the United States. 1 In Canada, .30% of the population is afflicted with chronic pain, and approximately 5% are taking codeine to manage pain at any given time. 2 Despite a wide variety of pharmacological agents available on the market, many people cannot achieve optimal analgesia, and inadequate treatment remains a major cause of suffering and dissatisfaction in pain therapy. 3 One cause for the variable success of pharmacologic pain therapy is different genetic polymorphisms affecting patients' pharmacodynamic response to analgesics.
Codeine, a commonly used opiate, acts on the mu-opiate receptor predominantly via its metabolite morphine, which is formed almost exclusively by the genetically polymorphic enzyme cytochrome P450 2D6 (CYP2D6). Although, in most people, 10% of codeine is biotransformed into morphine, multiple copies and multiple variations of the CYP2D6 gene affect the percentage of codeine conversion into morphine and hence the analgesia and toxic responses to codeine. There are currently .80 major CYP2D6 allelic variants described (http://www.cypalleles.ki.se/cyp2d6.htm). To simplify genotype interpretation, an activity score system that classifies individuals according to the number and functionality of their CPY2D6 alleles can be used to predict their CYP2D6 enzyme activity. 5, 6 Postpartum pain, due to either cesarean section (c-section) or episiotomy, is a major reason for the prescription of codeine, with an estimated 30% of North American women using the drug. 7 Several studies have examined the percent conversion of codeine into morphine for different CYP2D6 metabolizers, by measuring morphine serum concentrations as the endpoint. 3, 6, [8] [9] [10] [11] [12] These studies have identified that PMs convert very little codeine into morphine, whereas UMs can have plasma morphine concentrations about 50% higher than normal. However, there is much less information on the effect of CYP2D6 polymorphism on codeine pharmacodynamics. Only 4 studies have examined the effect of CYP2D6 on codeine analgesia: 2 using healthy volunteers 13, 14 and 2 in a clinical setting. 15, 16 Given the dearth of clinical studies, our objective was to study the relationship between CYP2D6 genotype and codeine analgesia, specifically among women postpartum.
MATERIALS AND METHODS
Patients and Study Design
This was a nested cohort study within a recently published randomized controlled trial. 17 All elective c-sections at St Michael's Hospital in Toronto were performed using the Pfannenstiel protocol. 18 Women who underwent elective c-sections received spinal anesthesia with 0.75% bupivicaine, and 15 mcg of fentanyl at induction, followed by 100 mcg of morphine administered epidurally at the end of surgery. Women were routinely monitored in hospital for 3 days and then discharged (ie, ;75 hours after surgery).
Post c-section, the following analgesia protocol was administered, unless noted otherwise: 1. A nonsteroidal anti-inflammatory (NSAID): naproxen (500 mg) rectally and then orally every 12 hours for 48 hours. All medication consumption was recorded. To evaluate the rate of postoperative recovery, we employed the Milestone Questionnaire, a scale used previously that comprises several items: time to first hunger, first spontaneous voiding, first ambulation, first bowel movement, and first eating solid foods after elective c-section. 19 
Outcome Measures
The primary endpoint for the study was the area under the curve (AUC) for pain in ambulation for days 1-3 using the visual analog scale (VAS), 20, 21 corresponding to the patient's total pain. VAS scores were collected (4 times a day) ranging from 0 (no pain) to 10 (maximal pain) from all women while they were in the hospital. The area under the VAS-time curve (AUC of pain) was calculated by plotting the VAS scores over time and using the trapezoid rule.
The following 7 secondary outcome measures were collected or calculated: 3-day codeine dose (total and milligrams per kilogram of body weight), 3 day NSAID dose (total and milligrams per kilogram), number of adverse events, peak pain (AUC of VAS scores on day 2), codeine dose day 2, genotype-adjusted morphine dose, and mean VAS pain scores. The following 2 covariates were collected and used in the multivariate analysis: mother's age and neonate's birth weight.
Genotyping CYP2D6
Blood samples for DNA extraction were collected from mothers during a routine blood draw in triage on the labor ward and then stored at 280°C. The blood samples from those women who took codeine-containing medication were genotyped for the presence of 15 CYP2D6 alleles [*2, *3, *4, *5 (gene deletion), *6, *7, *8, *9, *10, *12, *14, *17, *29, *41, *XN (gene duplication) by using AutoGenomics INFINITI Analyzer and the CYP450 2D6I Assay (AutoGenomics Inc, Vista, CA)]. These 15 polymorphisms are the most frequently occurring alleles identified; we included the most common alleles associated with poor (*3, *4, *5, *6), intermediate (*10, *17, *41), and increased metabolism (gene duplications) in different ethnic populations. 22 Alleles not carrying any detected mutations were classified as *1 (wild type).
Assigning a CYP2D6 Activity Score
To predict the CYP2D6 metabolizer phenotype, we used the activity score system 4, 6 whereby alleles with full CYP2D6 activity (*1, *2) are given a score of ''1,'' alleles with reduced activity (*9, *10, *17, *29, *41) a score of ''0.5,'' and inactive alleles (*3, *4, *5, *6, *7, *8, *12, *14) a score of ''0''. A genotype activity score that was obtained by summing the scores of the individual alleles in a given genotype was used to classify patients in 4 CYP2D6 phenotype classes as follows: PMs had an activity score of 0, IMs an activity score ranging from 0.5 to 1.5, EMs an activity score of 2, and patients carrying gene duplication in combination with 2 active alleles were classified as UMs.
Statistical Analyses
The statistical analyses were performed on SPSS software (IBM SPSS, version 17, Somers, NY). Descriptive statistics were calculated for the independent variables and were checked for normality. Multivariate and univariate (Spearman correlation) analyses were used to examine the relationship between CYP2D6 genotype and analgesic response. Because our sample size was small and the codeine 426 
Model Estimation of Genotype-Adjusted Morphine Dose
To evaluate whether genotype-adjusted morphine dose per kilogram can predict analgesia levels in a univariate model, we used the CYP2D6 activity score to estimate morphine dose.
Estimating Codeine Metabolism Rates
To estimate an individual's morphine dose, we commenced with the assumption that EMs (those with an activity score of 2) biotransform 10% of consumed codeine into morphine. 6 To account for genotype variability, a genotypecodeine conversion factor, as suggested by Kirchheiner et al, 6 was applied to the EM standard of 10% to account for increased or decreased morphine production according to the CYP2D6 genotype. The factors were derived by taking the ratio of plasma AUC of morphine over plasma AUC of codeine for each CYP2D6 (fine activity) genotype group 6 ; ratios for the groups are as follows: UM (activity score of 3) = 0.095; EM (activity score of 2) = 0.064; IM (activity score of 1.5) = 0.032; and PM (activity score of 0) = 0.003. These ratios were indexed to the EM group to develop a genotype-codeine conversion factor: 1.5 for UM, 1 for EM, 0.50 for IM, and 0.05 for PM.
RESULTS
Of the 80 women in the original randomized controlled trial, a total of 45 took acetaminophen with codeine for pain relief. Two women were not prescribed naproxen as first-line medication for analgesia and were instead only prescribed acetaminophen with codeine. No women were taking CYP2D6 or CYP3A4 inhibiting medications during their hospital stay. The majority of women reported feeling pain most acutely during the second day after the c-section. Patient characteristics for the 45 women are shown (Table 1 ). Of these 45 women, 3 were UMs (7%), 2 were PMs (4%), 26 were IMs (58%), and 14 were EMs (31%) ( Table 2) .
During days 1 and 2, a total of 3 pain scores, which represented ,1% of the data, were not collected because the patients were sleeping at the time of recording; all other data for patients were captured (pain medication consumption and time to first activity) on these days. However, on day 3, a total of 10 patients (22%) were discharged early (after 48 hours instead of after 75 hours in hospital) resulting in 22% missing data (pain scores, pain medication consumption, and time to first activity). The main endpoint (AUC of pain) and all other secondary measures were normally distributed, with the exception of codeine medication dose and adverse events, which were not normally distributed.
Three-day mean (6SD) pain AUC scores were 238 (6106) for the cohort; only the scores for the UMs seemed higher 408 (6102). Three-day mean (6SD) pain scores for the cohort were 3.5 (61.6); 3 genotype groups reported similar scores, with the exception of UM who reported 6.0 (61.5). Three-day median codeine dose was 180 mg; this was the same for all genotype groups except for the PMs, which was 450 mg. Three-day genotype-adjusted morphine dose ranged from 0.007 to 1.1 mg/kg (Table 3) .
Relation of Genotype to Pain Outcomes
Due to the very small number of extreme genotypes, this pilot study was underpowered to show the overall relationship between genotype and pain response. Multivariate analysis approached significance (F = 7.615, r 2 = 0.15) for the covariate of mother's age (beta = 27.736, P = 0.06) in explaining the AUC of pain. All other variables were nonsignificant: total codeine dose per kilogram (P = 0.99), total NSAID dose per kilogram (P = 0.92), neonate birth weight (P = 0.98), EM genotype group (P = 0.99), IM genotype group (P = 0.96), and PM genotype group (P = 0.99).
Similar results were achieved for multiple linear regression for peak pain (day 2), which was significant (F = 4.600, r 2 = 0.097) for mother's age (beta = 22.377, P = 0.038), whereas all other variables were nonsignificant: EM genotype group (P = 0.99), IM genotype group (P = 0.96), PM genotype group (P = 0.99), neonate birth weight (P = 0.94), day 2 NSAID dose milligrams per kilogram (P = 0.95), and day 2 codeine dose milligrams per kilogram (P = 0.88).
Analyses of Extreme Genotypes
Because the vast majority of patients were, as expected, EM and IM, we examined the pain and analgesia effects of our extreme cases (UMs and PMs). Pictorial representation of individual pain scores and codeine-containing medication consumption are shown (Fig. 1) .
Ultrarapid Metabolizers
Each of the 3 UMs had 1 of the factors associated with increased perceived pain after c-section identified by us recently 17 ; 2 were young (19 and 21 years old), and the third gave birth to a baby .4000 g. Despite the higher level of pain for these 3 women, 2 of the women requested only small doses of codeine-containing medication (60 mg once and 60 mg thrice, respectively) preferring, instead, to take acetaminophen and naproxen or naproxen alone for pain relief, due to dizziness and constipation. The third UM was not prescribed naproxen for 48 hours postsurgery as per protocol but instead was only prescribed codeine-containing medication prn to relieve pain. She took 540 mg of codeine-containing medication (60 mg, 9 times) throughout her 3-day hospital stay and, although she did not note any adverse effects, she had not yet had a bowel movement at the time that she was discharged from the hospital (75 hours postsurgery) ( Table 3) .
Poor Metabolizers
The 2 PMs were both .35 years old, a factor associated with less pain response after c-section. Despite lower pain levels, neither of these women reported any reduction in pain after consuming codeine-containing medication. One took 120 mg of codeine-containing medication (60 mg, twice) and then switched to acetaminophen because she did not feel that the codeine was relieving her pain. The other took 780 mg (60 mg, 13 times) over a 3-day period; although she also did not report any pain relief from codeine-containing medication, she had not yet had a bowel movement at the time of hospital discharge (75 hours postsurgery).
DISCUSSION
This study compared clinical pain relief among women of varying CYP2D6 genotypes who took codeine-containing medication after an elective c-section.
In our randomized trial published recently, 17 we identified 2 factors associated with women's perception of pain after c-section: mother's age (negative correlation) and neonatal birth weight (positive correlation). When the AUC of pain was regressed against total codeine consumption, total NSAID consumption, CYP2D6 genotype group, mother's age, and neonatal birth weight, the only significant factor was the mother's age. Older patients' experience of pain may differ from that of younger patients due to both physiological and psychological reasons, as has been suggested before. 23, 24 In addition, older patients have been reported to enjoy more pain relief than younger patients have, although receiving the same dose of medication. Our univariate and multivariate models examining CYP2D6 genotype and codeine dose showed no correlation with AUC of pain. We used pain AUC scores as a measure of total pain as this metric is simple to calculate, easy to explain, and captures 2 dimensions of the pain (magnitude and duration) in a single continuous measurement. 26 The lack of overall correlation between AUC of pain and genotype-adjusted morphine dose in the univariate and AUC of pain and codeine dose in the multivariate models is expected, due to the fact that most patients were EMs and IMs, with very small numbers of extreme cases in which CYP2D6 genotype has shown large effects.
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The potential effects of CYP2D6 genotype was illustrated in the individual cases of UMs and PMs, providing valuable insight into patients in whom CYP2D6 polymorphism is clinically relevant. Although 1 PM and 2 UMs had low doses of codeine-containing medication (ie, 120, 60, and 180 mg, respectively, over 3 days) to control breakthrough pain, the reasons for these low doses were markedly different. Both UMs stopped taking the drug because of adverse effects, unlike the PM who stopped because she did not feel that the codeinecontaining medication was helping her pain. In contrast, although the other PM also noted that the medication was not providing analgesia, instead, she repeatedly requested codeinecontaining medication, until she was receiving the maximum daily dose (60 mg every 4 hours for 3 days). The one UM prescribed high doses of codeine-containing medication was, unfortunately, not prescribed naproxen as per the standard analgesia protocol, and as such was left with little option for pain relief. The 2 UMs and 1 PM that took codeine-containing medication throughout their 3-day hospital stay had not yet had a bowel movement at the time of hospital discharge; this length of time is outside the mean (6SD) time for the cohort (60 6 13 hours). This is consistent with the finding in the previous literature showing that adverse effects arise from codeine ingestion, not just morphine, and occur regardless of CYP2D6 genotype status. 13 The strengths of this study include being one of the first studies to examine CYP2D6 genotype and codeine analgesia in a clinical setting, and the first to do so postpartum. Since one researcher collected almost all of the pain score and secondary data, she was able to collect qualitative information about the patient's pain and why patients switched from one medication to another. By capturing patients' personal reactions, we were able to discern the differences between UMs and PMs who discontinued their codeine medication-capturing an important clinical distinction.
Potential limitations of this study include a very small underpowered sample, not measuring individual codeine metabolism rates, the inability to control for various other factors both genetic and nongenetic and the use of an NSAID in addition to codeine medication for analgesia. Firstly, because the sample size was small, we did not have sufficient number of patients at the genetic extremes to identify a possible correlation to codeine analgesia. Secondly, while we were able to secure a blood sample for genotyping during a routine blood draw prior to surgery, the vast majority of women were unwilling to provide additional blood samples for pharmacokinetics of codeinecontaining medications for postpartum pain.
A large interindividual variability in response to codeine has been reported in an experimental study among both extensive metabolizers 27 and intermediate metabolizers 28 and this has not been captured in this paper. In addition, the *1 allelic variant was assigned as a default if none of the other 14 alleles were present, so some rarer alleles could have been missed. Both of these conditions mean that the interpretation of genotypes and the resulting estimate of codeine and metabolites may be over or underestimated.
Thirdly, there are genetic factors which may modify the effect of morphine, including variability in the expression or signaling of the mu-opioid receptor, 29, 30 variability in the MDR1 gene which codes for P-glycoprotein used for drug transport, 31 variability in other codeine metabolizing enzymes such as CYP3A, 32 and UGT2B7.
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Fourthly, there are also nongenetic effects such as variations in CYP3A activity due to pregnancy 34 and surgery 35 and nongenetic factors such as age, race, mood, and coping ability. 36 Moreover, large variability in the process of nociception 37 would lead to great interpatient variability in recorded pain scores and the desire for pain medication. The inability of the pain scores to differentiate patients may be due, in part, to issues other than pain severity. Concerns about adverse effects, medication interactions, and addiction, may all contribute to the decision to accept or reject treatment. 38 Finally, while our analgesic protocol follows the WHO analgesic ladder for progressive treatment of increasing pain 39 this cannot lead to the assumption that the effect of the NSAID was similar across all women.
CONCLUSIONS
In this pilot study, extreme CYP2D6 genotypes seemed to predict pain response or adverse effects. To study the impact of the whole range of genotype-phenotype combinations on the pharmacodynamics of codeine, these observations need to be confirmed in a much larger cohort, with higher proportions of UMs and PMs.
